医学
恶化
慢性阻塞性肺病
随机对照试验
肺康复
物理疗法
不利影响
康复
内科学
作者
Anja Frei,Thomas Radtke,Kaba Dalla Lana,Patrick Brun,Thomas Sigrist,Marc Spielmanns,Swantje Beyer,Thomas Riegler,Gilbert Büsching,Sabine Schöndorf,Julia Braun,Ramona Kunz,Tamara Cerini,Milo A. Puhan
标识
DOI:10.1183/13993003.congress-2021.oa2939
摘要
Introduction: A majority of COPD patients fails to maintain training after pulmonary rehabilitation (PR). Objective: To assess the effectiveness of the newly developed, home-based, minimal equipment HOMEX strength exercise program in COPD patients over 1 year. Methods: COPD patients from 4 Swiss PR clinic were randomized into intervention (IG) or control group (usual care, CG). Primary outcome was change in dyspnea (Chronic Respiratory Questionnaire; CRQ) from baseline to 12 months, secondary outcomes change in exercise capacity (1-minute-sit-to-stand-test, 6-minute-walk-test), health status, exacerbations and symptoms. Adjusted linear regression models were used. Results: 123 COPD patients (IG: 61, CG: 62) were randomized; 61 females, age 66.8 (8.1) years, FEV1% predicted 39.4 (15.4). 104 participants completed 12-months follow-up (IG: 53, CG: 51). During the study year, 76 participants experienced at least one exacerbation [2.3 (1.6)] and 68 at least one serious adverse event (135 in total). Out of the 53 IG participants, 38 conducted the HOMEX training until study end and 43 for at least 10 months. We found no difference in change of CRQ dyspnea in one year (mean difference 0.28, 95% CI -0.23-0.80, p=0.27). There was a statistically significant difference in 1-minute-sit-to-stand test repetitions favoring the IG after one year (mean difference 2.6 (95% CI 0.22-5.03, p=0.033). In all other outcomes, no significant differences between the two groups were found. Conclusions: Our results show that the HOMEX training provided benefit in functional exercise capacity assessed by the 1-minute-sit-to-stand test. This intervention is a promising approach to maintain the effects after PR long term.
科研通智能强力驱动
Strongly Powered by AbleSci AI